Supporting the Innovators who Optimize Therapeutic Decision-Making
Crosstree’s experience in the diagnostics and tools space is extensive, spanning routine chemistries to the most esoteric of testing, via either a product or service commercial approach. Molecular biology is reshaping the competitive landscape and Crosstree is at the forefront, facilitating synergistic transactions for a range of innovators in genomic and genetic testing and development.
No other partner is so uniquely equipped to assess and align the capabilities of diagnostics and tools companies with current market demands.
Diagnostics and Tools
Life Sciences
Tools
In Vitro
Diagnostics
Diagnostic
Services
In Vivo
Diagnostics
LIFE SCIENCES TOOLS
- Consumables
- Instrumentation
- Lab/Biobank Equipment
- Laboratory Software
IN VITRO DIAGNOSTICS
- Chemistry
- Hematology & Coagulation
- Histology & Cytology
- Immunodiagnostics
- Microbiology
- Molecular
DIAGNOSTIC SERVICES
- Diagnostic Imaging
- General Chemistry
- Specialized Testing
- Toxicology
IN VIVO DIAGNOSTICS
- Biometric Monitoring
- Imaging Diagnostics
Bluebooks
Explore our industry-specific Bluebooks for comprehensive monthly coverage of M&A, recapitalization, and growth financing transactions, along with year-on-year comparisons. Subscribe to your relevant BlueBook for valuable insights today.
Latest Diagnostics and Tools Transactions
.png)
.png)
Sengenics, a Portfolio Company of Summa Equity, Acquired by Standard BioTools
Bio-Techne Divested Assets of Its Subsidiary, Atlanta Biologicals, to GeminiBio
BBI Solutions, a Portfolio Company of Novo Holdings, Acquired IBEX Technologies Inc. to Bolster Recombinant Protein Offering
Grant Avenue Capital Recapitalizes CREO
QDx Pathology, a Portfolio Company of Hadley Capital, Acquired by LabGenomics to Expand Esoteric Testing Capabilities Globally
